Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1500648800HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Ferring takes option on TxCell's IBD cell therapy

18.03.2014 / Scripintelligence

Privately-held French biotech TxCell and Ferring of Switzerland have signed a collaboration agreement potentially worth up to €76m plus royalties for TxCell's lead product Ovasave for the treatment of inflammatory bowel disease (IBD).

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: